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Abstract
Mrg receptors are orphan G protein-coupled receptors (GPCRs) located mainly at the specific set of
sensory neurons in the dorsal root ganglia, suggesting a role in nociception. We report here the 3-D
structure of rat MrgA (rMrgA) receptor [obtained from homology modeling to the recently validated
predicted structures of mouse MrgA1 and MrgC11] and the structure of adenine (a known agonist,
Ki=18nM) bound to rMrgA. This predicted binding site is located within transmembrane helical
domains (TMs) 3, 4, 5 and 6, with Asn residues in TM3 and TM4 identified as the key residues for
adenine binding. Here the side chain of Asn88 (TM3) forms two pairs of hydrogen bonds with N3
and N9 of adenine while Asn146 (TM4) makes two pairs of hydrogen bonds with N1 and N6 of
adenine. These interactions lock adenine tightly in the binding pocket. We also predict the binding
site of guanine (not an agonist) and seven other derivatives. Guanine cannot make the hydrogen bond
to Asn146 (TM4), leading to binding too weak to be observed experimentally. The predicted binding
affinity for other adenine derivatives correlates with the availability of the hydrogen bonds to these
two Asn residues. These results validate the predicted structure for rat MrgA and suggest mutation
experiments that could further validate the structure. Moreover the predicted structure and binding
site should be useful for seeking other small molecule agonists and antagonists.
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Introduction
The superfamily of G protein-coupled receptors (GPCRs) is one of the most important classes
of membrane proteins, being involved with both cell-to-cell communication and sensory
response neurons. Binding of an agonist in the extracellular region activates the GPCR, which
in turn activates the heterotrimeric G protein present in the cytosolic domain. This is coupled
to the intracellular region of the receptor, regulating downstream signaling pathways in the
cell. Important GPCRs include receptors for dopamine, serotonin, and acetylcholine
neurotransmitters and for bradykinin and endothelin neuropeptides. GPCRs are also found in
various sensory neurons related to smell, taste, pain, and vision. Despite their important roles
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in biological functionality ~1/3 of the 500 human nonsensory GPCRs remain orphans [1]. Thus
it is important to identify the endogenous ligands for these orphan GPCRs.
Recently several groups[2–4] have identified from mouse, rat and human genes a family of
new orphan receptors in the specific subset of dorsal root ganglia, suggesting a role in
nociception. These receptors have been denoted as sensory neuron-specific receptors (SNSRs)
or MAS-related gene (Mrg) receptors. Several studies have been carried out to identify the
cognate ligands [5–8]. Most agonists are neuropeptides, such as FMRFa, or peptides similar
to fragments of endogenous opioid peptides. However, rat MrgA has been shown to be
activated by adenine (and not guanine). Indeed adenine activates rMrgA with a Ki value of 18
nM, potentially identifying it as the endogenous ligand [4]. Another example is mouse MrgD
that is activated by beta-alanine (EC50 = 44 μM) [6].
The characterization of the ligand binding site is an important first step in identifying the
endogenous ligand for orphan receptors, and it is particularly important for designing new
ligands that could aid in determining the function of these receptors and possibly remedying
any disease associated with them.
In this paper we predict the 3-D structure of the rMrgA receptor, and we report the ligand
binding site for adenine and related ligands. This work builds upon our recent studies in which
we first predicted the 3-D structures of mouse MrgC11 (mMrgC11) and MrgA1 (mMrgA1)
receptors using the MembStruk computational method [9,10]. These structures were validated
by predicting the binding sites and energies for several tetrapeptides, identifying key residues,
and then experimentally confirming the expected changes in binding resulting from mutations
of these residues.
For this study on rMrgA, we use these validated mMrgC11 and mMrgA1 structures as
templates to predict with homology modeling the 3-D structure of rMrgA receptor, which has
49 % and 77 % sequence identity with mMrgC11 and mMrgA1 respectively. Then we used
this structure of rMrgA in conjunction with the HierDock computational procedure to predict
the binding site of all nine ligands to the rMrgA receptor for which experimental data is
available. We also compare the putative binding site of rMrgA receptor with those of other
known adenine-related GPCRs like adenosine receptors and purinergic receptors.
Computational methods
Molecular modeling of receptor structure
Starting with the 3-D structures for mMrgC11 and mMrgA1[11] as templates, we used
MODELLER6v2 (University of California San Francisco, San Francisco, CA) to build a
homology model for the 3-D structure of rMrgA receptor. The sequence of rMrgA receptor
(TrEMBL accession number: Q7TN49) was aligned with mMrgC11 (TrEMBL accession
number: Q8CIP3) and mMrgA1 (TrEMBL accession number: Q91WW5) using Clustal-W
(version 1.82) [12] as shown in Fig. 1. The sequence identity of rMrgA with mMrgC11 is 49
%, while that for mMrgA1 is 77 %, for the entire sequences. The TM regions have 44 to 76 %
identity (totaling 56 %) between rMrgA and mMrgC11 and 77 ~ 88 % identity between rMrgA
and mMrgA1 (totaling 83 %). The mMrgC11 and mMrgA1 structures were predicted [11]
using the MembStruk computational protocol, and validated by
1. using the HierDock computational protocol to predict the binding site for a series of
tetrapeptides established experimentally to bind (~100 nM),
2. identifying the critical residues for binding these ligands,
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3. experimentally building 6 mutations in the binding site (3 of which were predicted to
bind ~100 times worse and 3 of which were predicted to bind similarly),
4. experimentally verifying the predictions.
The MembStruk and HierDock protocols have also been applied to other GPCRs including
bovine rhodopsin receptor [10], human dopamine D2 receptor [13], human β2 adrenergic
receptor [14] and several olfactory receptors [15–17]. In each case the key interactions observed
in the experiments are identified from our prediction, validating that these methods can predict
the 3D structures of the proteins and the binding sites of strongly bound ligands to these sites.
After predicting the overall 3-D structure of rMrgA by homology-modelling, the side chain
conformations were re-assigned using the SCWRL3.0 side chain replacement program (~1.4
Å diversity),[18] and hydrogen atoms were added using the POLYGRAF software. The all-
atom structure was optimized with the conjugate gradient minimization technique to an RMS
in force of 0.5 kcal/mol/Å. Subsequently, this minimized receptor structure was used as the
starting point for gas phase NVT molecular dynamics (MD) simulations (using an internal
dielectric constant of 2.5) at 300 K for 10 ps to account for changes in the backbone
conformation. The conformation with the lowest total energy in the trajectory was selected and
minimized to an RMS force of 0.5 (kcal/mol)/Å. All simulations used the DREIDING force
field (FF) [19] with charges from CHARMM22 [20] in the MPSim code [21]. The cell
multipole method [22] was used for calculation of non bond interaction.
QM calculation of ligand tautomers
We docked to rMrgA the 9 molecules shown in Fig. 2 (including adenosine phosphates), for
all of which there are measured binding constants. The structures for these molecules were
constructed using the Cerius2 build module (Accelrys Inc., San Diego, CA). The ligand
conformations were minimized using conjugate gradients with the DREIDING FF and
GASTEIGER charges [23]. For ligands with a significant number of torsions, such as 6-
benzylaminopurine (6BAP), adenosine and adenosine phosphates, the x-ray crystal structures
were obtained from the Cambridge Structural Database and used as the starting conformation
for docking without further optimization.
For 1-methyladenine (1MA) and 6BAP, several tautomeric forms are possible in addition to
the direct substitution at N1 or N6 of adenine. For these systems we built all such tautomeric
forms (see Fig. 2) and calculated their relative stabilities using quantum mechanics (QM) to
determine the dominant tautomeric form.
The QM calculations used the B3LYP version of density functional theory which includes both
the Becke generalized gradient approximation of exact Hartree-Fock exchange [24] and the
LYP correlation functional [25], as implemented in the Jaguar v5.5 software (Schrodinger,
Portland, OR). The geometries were first optimized in the gas phase using the 6-31G** basis
set. The vibrational frequencies for thermodynamic quantities were calculated at the same level.
The calculated frequencies were scaled by the factor 0.9614 appropriate for B3LYP/6-31G*.
All thermodynamic quantities were computed at 298.15K, based on standard ideal-gas
statistical mechanics and the rigid-rotor harmonic oscillator approximations. We calculated
the solvation energy in water using the Poisson-Boltzmann methodology with standard
parameters [dielectric constant εH2O = 80.37, solvent probe radius RH2O = 1.40 Å, and Dreiding
van der Waals radii of atoms] for the final optimized QM structure. These results are in Table
S1 of the supplementary information.
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Scanning the receptor to determine the putative binding region
To select the putative binding region, we used adenine (the best binder) to scan the entire
receptor structure of rMrgA. To do this we first calculated the molecular surface using autoMS
utility in DOCK4.0 [26] with the default values for surface density (= 3.0 dots/Å2) and probe
radius (= 1.4 Å). Then we used SPHGEN in DOCK4.0 to generate spheres from each surface
point to fill up the void space in the receptor. The receptor was partitioned into 41 cubic boxes
with each side of 10 Å such that all void spheres were included. The spheres inside each box
were taken as an input for DOCK4.0 to define the docking region. The scoring energy grids
of the protein were calculated using GRID in DOCK4.0, with a grid spacing of 0.3 Å and a
nonbond cutoff distance of 10 Å. For each of the 41 regions, we performed rigid docking with
the anchor search option in DOCK4.0. For each region, we sampled orientations until 100
passed the bump test and then we selected the ten top scoring orientations. For each of these
10 from each of the 41 boxes, we used MPSim to minimize the ligand conformation with the
receptor coordinates fixed to obtain the final energy scores. Here we used the Dreiding FF.
After scoring with MPSim, we calculated the percentage of buried surface for each of these
410 orientations using the Connolly MS program from Quantum Chemistry Program Exchange
(QCPE). Of these, 103 had over 90 % of buried surface. From these we selected the best
orientation for each box. Out of the 41 boxes, this led to seven possible binding regions with
good energy and > 90 % buried surface. We then clustered the spheres near these seven regions,
to obtain the two distinct putative binding sites shown in Fig. S1.
Docking adenine and guanine into the predicted putative binding sites
The HierDock protocol was used to predict the binding site and energy of adenine to both
binding regions. This protocol has been used for several GPCRs [9,10,13,14,16,27,28], outer
membrane protein A [29], and globular proteins [15,30–34]. In this paper we used the modified
HierDock protocol (MSCdock) described in Cho et al. 2005 [35]. Briefly, this uses a modified
DOCK4.0 to generate a complete set of families of ligand configurations differing by a diversity
of 0.60 Å. Here we used a rejection ratio of 2.2 to define completeness (leading to 2,453 families
that passed the bump tests). We then enriched the top 75 families until there was an average
of six members in each family (passing the bump tests). Then we scored these using MPSim
(Dreiding FF) and selected the 30 best scoring family heads. These were minimized (conjugate
gradients) using MPSim (50 steps or 0.1 kcal/mol/Å) with ligand movable and the receptor
atoms fixed. Then the 5 best scoring ligands (total energy) were selected and the side chain
conformations of the residues of the receptor within 5 Å of the bound ligand were reassigned
using the SCREAM side chain replacement program [Kam, Vaidehi and Goddard in
preparation] (This uses a side chain rotamer library of 1 478 rotamers with 1.0 Å resolution,
with all atom DREIDING energy function to evaluate the energy for the ligand-receptor
complex). The binding energies were then calculated for these 5 optimized ligand-receptor
complex structures as the difference between the energy of the ligand in the fixed receptor and
the energy of the ligand in solution. The energy of the free ligand was calculated for the docked
conformation and its solvation energy was calculated using Analytical Volume Generalized
Born (AVGB) continuum solvation method [36]. The dielectric constants for the continuum
solvation method were set to 78.2 for the external region and to 1.3 for the internal region.
Guanine shows no binding in the experiments (worse than ~ 100 μM). We docked it to the two
putative binding regions determined from scanning the receptor (shown in Fig. S1).
Refinement of the binding mode of adenine
To account for changes in the backbone structure of the receptor due to ligand binding, we
started with the docked structure and carried out annealing MD simulations allowing the ligand
and residues within 10 Å in the binding pocket to move (with other residues fixed). The
procedure was to heat the system from 50 K to 600 K and then to cool it back down to 50 K
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in steps of 50 K. At each temperature the velocities were first scaled to obtain the correct initial
kinetic energy and the system was then equilibrated for 1ps using the Nose thermostat (NVT).
Thus the total MD time was 23 ps. At the end of the annealing cycle, the system was minimized
to an RMS force of 0.3 (kcal/mol)/Å and the side chains of the residues within 5 Å from the
ligand were reassigned again with SCREAM.
Docking of other adenine derivatives
After optimizing the structure for adenine in the receptor, we re-clustered the spheres to define
the binding site. Spheres within 1.0 Å from any atom in the docked adenine were selected out
of the entire spheres generated for the final receptor structure that was previously optimized
with adenine. We then used the HierDock procedure described above to dock the adenine
derivatives.
Results and Discussion
Characteristics of receptor structure
The sequence identity of rMrgA receptor with bovine rhodopsin is ~18 % for TM regions (the
averaged value obtained with the independent alignments for each TM). The RMSD of the
coordinates of the Cα atoms between our model of rMrgA and the X-ray structure of rhodopsin
is 3.72Å in TM regions [37].
The RMSD of rMrgA with mMrgA1 (83 % sequence identity for TM regions) is 0.41 Å in the
TM regions and the RMSD with mMrgC11 (56 % sequence identity for TM regions) is 2.59
Å in the TM regions (the sequence alignment is shown in Fig. 1). The predicted 3-D structure
of rMrgA is shown in Fig. 3b where it is superimposed with the predicted structures of mMrgA1
and mMrgC11. The MODELLER program uses restraints based on weighted Gaussian
distribution functions, where the weighing factor depends on the local sequence similarity.
Thus the rMrgA loops involved some weighting of the loops from of mMrgA1 and from
mMrgC11.
Fig. 4 shows the interhelical hydrogen bond network in TM regions formed in the rMrgA
receptor;
• The Asn31 (TM1) makes hydrogen bonds with the side chain of Asp58 (TM2) and
the backbone carbonyl of Cys256 (TM7) at the same time and contributes to the
interhelical stability among TM1, TM2 and TM7. This Asp-Asn pair is highly
conserved across the family A of GPCRs, corresponding to Asp83 and Asn55 in
bovine rhodopsin. There is a similar pattern in rhodopsin structure [38] where a
carbonyl group of A299 in the backbone of TM7 is the common hydrogen bond
acceptor for Asn55. In mMrgA1, these homologous residues form the same pattern
of hydrogen bonds.
• The Tyr95 (TM3) is conserved throughout the Mrg receptor family (although 5 of 36
have a Phe conservative replacement at this position). Here the hydroxyl group of Tyr
forms an interhelical hydrogen bond with a backbone carbonyl group of C218 in TM6.
The mMrgA1 has the same interaction with these homologous residues, but in the apo
mMrgC11 receptor this conserved Tyr residue participates in aromatic interactions in
TM regions [11].
• The highly conserved Asn53 (TM2) and Trp136 (TM4) form a hydrogen bond as
observed in rhodopsin (Asn78 and Trp161), which we also find in both mMrgA1 and
mMrgC11.
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• One more hydrogen bond pair exists between Ala46 (TM2) and Thr129 (TM4) near
the intracellular region. This interaction is unique for rMrgA, although the Thr is
conserved in mMrgA1.
• In addition, the positively charged residue Arg147 (TM4) is oriented slightly towards
the lipids and might make contact with the negatively charged head group of the lipid
molecule. We find that it forms hydrogen bonds with Cys86 and Thr89 in TM3 that
are one helical turn apart. Arg147 is replaced by Ser and Trp in mMrgA1 and
mMrgC11 respectively, which do not participate in interhelical hydrogen bond
interactions.
The highly conserved proline residues in TM6 and TM7 across the family A of GPCRs
correspond to Pro221 (TM6) and Pro258 (TM7) in rMrgA receptor. They lead to bends of 15°
and 18° in the α-helix structure.
The Pro94 (TM3) in rMrgA receptor corresponds to the double Gly in the middle of rhodopin.
In both cases this leads to bending (19° for rMrgA and 13° for rhodopsin), making the overall
backbone conformation of TM3 in these two receptors similar.
QM results of ligand tautomers
The QM results of the free energies for the different tautomeric forms (Fig. 2) of 1MA and
6BAP are shown in Table S1. We find that in solution the free energy of 1MA1 is 1.87 kcal/
mol lower than that of 1MA2. The relative abundance with respect to the tautomer with the
lowest free energy was calculated from the free energy using the equation;
tautomer
tautomer lowest
= exp ( − ΔGsol / RT )
where R is the gas constant (= 1.986 cal/mol K) and T is the temperature (= 298.15 K). Thus
we predict that the relative abundance of 1MA2 is only ~4 % of 1MA1 [In contrast 1MA1 is
less stable than 1MA2 by 3.5 kcal/mol in the gas phase.].
There are three tautomers for 6BAP, but 6BAP1 is the most stable both in gas phase and in
aqueous solution. Here the others forms have negligible abundance.
These calculations suggest that the majority species for 1MA or 6BAP have direct substitution
at the N1 or N6 of adenine. All tautomeric forms were chosen for the docking studies and it
turned out that these directly-substituted forms showed the best binding energy.
Location of the Binding site
MSCdock predicts that the adenine binding site lies among TM3, TM4, TM5 and TM6 as
shown in Fig. 3. This TM3-4-5-6 pocket (corresponding to region 2 in Fig. S1) is predicted to
provide the binding site for the agonists to a number of other GPCRs (including dopamine,
adrenergic, histamine). In addition the adenine is in a region similar to the β-ionone ring of 11-
cis retinal in bovine rhodopsin (but the adenine leans more towards TM4 instead of TM6).
The scanning step also found a second binding site, denoted as region 1 in Fig. S1. This other
site is located in the interhelical hydrogen bond network among TM1, TM2 and TM7. In this
site both adenine and guanine make a hydrogen bond with the highly conserved Asp58 in TM2,
but the binding pocket is mostly hydrophobic except for this Asp residue. We found that the
calculated binding energy of adenine in region 1 is only 66 % of that in region 2. The binding
energies of guanine in region 1 and 2 were 73 % and 78 % respectively, of that for adenine in
region 2. Thus we conclude that this site is not the site for agonist binding (it could play a role
for antagonists).
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As discussed previously, Asp58 (TM2) plays a key role in stabilizing the TM1, 2, 7 triad, and
it may be the site at which Na+ binds for the allosteric regulation observed in human adenosine
A1 receptor and α2A adrenergic receptor [39,40], making it unlikely to serve as the agonist
binding site.
Based on these results we ruled out region 1 as a possible binding site.
Predicted Binding site of Adenine
Adenine is reported as the potential endogenous ligand for rMrgA receptor by Bender et al.
[4] The binding mode is detailed in Fig. 5a. The most critical residues for binding are Asn88
(TM3) and Asn146 (TM4). They each form bidentate hydrogen bonds with adenine, locking
it tightly inside the pocket. The hydrogen bond partners of Asn146 are the same nitrogen atoms
of adenine that participate in the DNA base pair. In addition Phe83 in TM3 and His225 in TM6
have good π stacking interactions with the purine ring. These features characterizing adenine
binding site agree well with the empirical observations by Nobeli et al. to explain the molecular
discrimination of adenine and guanine ligand moiety in complexes with proteins [41]. They
observed that the protein aromatic residues stabilize an environment in which the ligand would
have π stacking interaction with the side chain of these residues and that His is much more
favorable for adenine. They found that amino acids with side chains like Asn that can form
simultaneously a donor hydrogen bond and an acceptor hydrogen bond are favored for binding
adenine.
For mMrgC11 the di- and tetra-peptide agonists were both predicted to bind to in the TM3-4-5-6
pocket [11]. Asn146 (TM4) is homologous to Asp161 in mMrgC11, which was identified as
a key residue in ligand binding. However, Asn88 is replaced by Gly in mMrgC11 so that
adenine is not expected to bind to mMrgC11. The hydrophobic interaction of Leu174 (TM5)
was also found in the predicted binding site of mMrgC11.
The residues within the binding pocket in Fig. 5 are grouped by color according to the
intermolecular interaction energy with the ligand (red is strongest, blue is weakest). Here the
intermolecular interaction energy includes Coulomb, van der Waals, and hydrogen bond terms.
The most important are Asn88 and Asn146, which show strong hydrogen bond interactions.
Met92 has moderate van der Waals interaction with adenine.
Predicted Binding site of Guanine
Changing the docked adenine structure to guanine, we find that the hydrogen bond donor and
acceptor in the side chain of Asn146 do not match with the counterparts in guanine, resulting
in a decrease in the predicted binding energy (by 17 % compared to that for adenine) for guanine
in this configuration. However N2 of guanine forms a new weak hydrogen bond with sulfur
of Cys150.
Independently docking guanine, leads to a structure in which the guanine has the different
orientation shown in Fig. 5b. Here its hydrogen bond interactions with Asn146 are not optimal.
The carbonyl group of the Asn146 side chain loses a hydrogen bond partner and the Asn146
amine group does not make a good hydrogen bond. However the guanine retains similar
interaction with the other residues.
Thus the predicted structure of rMrgA, explains the dramatic difference in bonding between
adenine and guanine. Adenine can bind to both Asn in the active site leading to good hydrogen
bonds for N1, N3, N6, and N9. In contrast guanine in the same configuration could make only
half of these. As a result guanine binds in an alternate site where the sidechain of Asn88 forms
hydrogen bonds with the N1 and O6 atoms of guanine and Asn146 forms a weak hydrogen
bond with N7, but having 78 % less binding energy than adenine. However if Tyr95 that is
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found nearby N2 and N3 of guanine is mutated to Gln, formation of two more hydrogen bonds
would be expected and might enhance the binding affinity in spite of the loss in van der Waals
interactions. Indeed the predicted binding energy of guanine in the Tyr95Gln mutant is
comparable to that of adenine in the wild type (99.9 % of adenine binding).
The total intermolecular interaction energy and its each component in the binding pocket
composed of residues within 5 Å from the bound ligand are tabulated in Table 1.
Predicted Binding Site of Medium Binders
For 1MA (Ki=4.4 μM) we also calculated two binding modes, one by perturbing adenine to
1MA, the other with independent docking. The binding modes of 1MA are described in Fig.
6. The perturbed structure built by direct substitution at N1 in the docked adenine leads to a
big clash between the bulky methyl group and Asn146. The independently docked 1MA is
locked between Asn88 and Asn146 through hydrogen bonds with these two residues. However,
this leads to slightly weakened bonding with Asn146 due to the loss of one of the hydrogen
bonds. This leads to a predicted binding energy of 83 % relative to that to adenine. The methyl
substituent of 1MA resides in the good hydrophobic environment.
For 6BAP, another mild binder (Ki=58 μM), we find a docking orientation similar to that of
1MA. Here the large benzyl substituent has a close contact with Tyr95 with good π stacking
interactions making the van der Waals term the dominant non bond interaction. 6BAP also
forms hydrogen bonds with Asn88 and Asn146, but the interaction with Asn146 is weaker than
for adenine or 1MA. The loss of this interaction is partly compensated by the increased van
der Waals interactions as shown in Table 1. The result is a binding energy of 92 % relative to
that of adenine.
Predicted Binding site of Poor Binders
Hypoxanthine, one of the bad binders, makes nice contacts with Asn146 but has weak
interactions with Asn88. Its hydrogen bond energy is comparable to 6BAP in Table 1, but the
van der Waals interaction energy is insufficient to overcome the decreased hydrogen bond
energy. The result is a binding energy of 71 % relative to that of adenine.
For adenosine, we find that only Asn88 makes good hydrogen bond contacts with the ligand,
with no other residues having good specific interactions. The result is a binding energy of 71
% relative to that of adenine.
Predicted Binding site of adenosine phosphates
Adenosine mono- and tri-phosphates (AMP and ATP) are observed to have binding constants
to rMrgA in the range of 20–60 μM concentration. Our predicted structures are in Fig. 7. We
find that the adenine moiety forms two good hydrogen bonds with Asn88, but they have
different glycosyl torsion angles. In both cases the sugar ring has a contact with Asn146. We
find that the phosphate group points toward extracellular region and is stabilized by Arg147
in TM4 (on the boundary between the inside-bundle region and the membrane). This is the
only positively charged residue located on the upper half of TM regions (excluding a Lys233
at the end of TM6). This further validates our prediction of binding site.
For neutral ligands such as adenine, the side chain of Arg147 leans more toward the membrane
regions which might allow it to contact the head group of lipid as seen in the apo protein in
Fig. 4. However when the phosphate comes into the binding pocket, the Arg147 would move
toward the pocket.
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For adenosine diphosphate (ADP), the sugar ring interacts with Asn146 in the similar way to
AMP but the adenine base does not interact strongly with Asn88 (see Fig. 7c). The phosphate
group shows strong interaction with Arg147 and Thr89.
Comparison of calculated binding energy to ln Ki
The predicted binding energies for the various ligands are compared in Fig. 8 with the
experimental competition binding constant (inhibition constant) reported by Bender et al. [4]
Of the nine compounds whose binding constants have been measured, we examined only the
six neutral ligands with the fewest torsional degrees of freedom (since the adenosine phosphates
are highly negative-charged, the entropic effect in binding is no longer negligible and the
uncertainty in calculated solvation energy increases). Fig. 8 shows the good correlation
between our calculated binding energy and the experimental inhibition constant, ln Ki. The
calculated binding energy distinguishes the poor ligands and shows qualitative agreement with
the experimental affinity among the good or medium binders. The calculating binding energy
is for the minimized structure at 0 K, which ignores entropic effects. Except for adenosine and
6BAP all ligands are rigid with similar shapes so that the entropic contributions should be
similar. Thus, the predicted reverse ordering for 1MA and 6BAP in the predicted binding
energy might arise from differential entropic effects (due to loss of translational and rotational
entropy and the loss of internal degrees of freedom within the ligand and in the amino acid side
chains) in comparing the binding between the more diverse ligands. These factors become
larger for a bulkier ligand. Nevertheless, this overall good correlation provides additional
validation of our predicted structures and binding configurations.
Effect of Computational Alanine-scanning mutations (CASM) in the binding pocket
For the best binder, adenine, we carried out alanine scanning to assess the importance of various
residues to binding. The residues within 5 Å of the ligand were each independently mutated to
Ala and the energy for the ligand-protein complex was reoptimized (conjugate gradient
minimization). Prior to the minimization we used SCREAM to reselect the side chain
conformations of the other residues within 5 Å of the ligand. The results are summarized in
Table 2.
As expected, the Asn88Ala and Asn146Ala mutations significantly reduce the binding affinity
due to the loss of the hydrogen bonds. Mutation of either Phe83 or His225 abolishes the
favorable van der Waals contacts.
The close correspondence between the contributions predicted for the wild type and the change
in bonding calculated with the mutation to Ala, indicates that good estimates can be made
without optimization of the coordinates.
Comparison of the adenine binding site in rMrgA to the nucleotide binding sites in adenosine
receptors and purinergic receptors
We can compare the binding site of adenine to rat MrgA with the binding site of human A1
and A2A adenosine (hA1A and hA2AA) receptors and human P2Y1 purinergic (hP2Y1)
receptor. These receptors all bind adenosine or ATP, with the adenine moiety in common, and
all have been studied both experimentally and with modeling. The sequences of the adenosine
receptors and the purinergic receptor were aligned separately with that of rMrgA receptor. The
whole sequences were aligned first with Clustal-W while ensuring that specific highly
conserved residues are matched to each other in the alignment: Asn at position 20 in TM1, Asp
at position 13 in TM2, Arg in DRY sequence of TM3, Trp at position 12 in TM4, Pro at position
19 in TM6, Pro in NPXXY of TM7 (the number is counted from the starting residue of each
TM in Fig. 9). Using the TM prediction of rMrgA receptor, the sequences for each TM were
aligned independently. The averaged sequence identity of rMrgA receptor is ~22 % for hA1A
Heo et al. Page 9
J Mol Graph Model. Author manuscript; available in PMC 2008 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
receptor and ~20 % for hA2AA receptor (considering only TM regions). For hP2Y1 receptor,
the TM sequence identity to rMrgA is ~24 %. The resulting TM sequence alignment is shown
in Fig. 9 where the key residues in adenosine receptors and P2Y1 receptor identified from the
binding or functional assay experiments are bolded and underlined [42,43].
Recall that for rMrgA the adenine binding site is located in the pocket of TM3, TM4, TM5 and
TM6, contacting Asn88 (TM3), Asn146 (TM4), Leu174 (TM5) and His225 (TM6).
In the putative A2A binding site, the adenine moiety is recognized by TM3, TM5 and TM6
[42]. The binding regions in TM3 overlap significantly throughout four receptors but we could
not find any residue from adenosine or purinergic receptor that directly matches with Asn88
in rMrgA receptor. However, Gln92 in TM3 of hA1AR has the same functional group as Asn
(shorter by one methylene) which was found to interact with the adenosine adenine moiety
[44]. Asn146 in TM4 is a key residue in the adenine binding in rMrgA, but no similar residue
is identified as a key residue in TM4 of adenosine or purinergic receptor. Arg157 in TM4
interacts with phosphate group of adenosine phosphates in rMrgA while Lys (TM6) and Arg
(TM7) are involved in P2Y1 receptor.
In conclusion, although similar residues recognize adenine, there is very little similarity in the
location of the binding site of adenine in rMrgA receptor compared to adenosine and purinergic
receptors. This suggests that rMrgA belongs to non-adenosine or non-purinergic receptor
families even though adenine binds well and activates the receptor.
Comparison to other MrgA orthologs
We examined the sequences of the 8 mouse orthologs of rMrgA receptor to determine whether
some might be good candidates for possible adenine binding receptors. These are collected
together and compared to rMrgA in Fig. S2. Among the eight mouse MrgA (mMrgA) receptors,
we find that the mMrgA2 receptor has Asn residues at the same two positions in TM3 and TM4
as in rMrgA receptor. However, Bender et al. tested activation of the mMrgA2 receptor with
adenine and found no activation [4]. Perhaps this is because the mMrgA2 receptor does not
have a proline in the middle of TM3 analogous to the Pro94 of the rMrgA receptor that we
found to induce the bend in TM3. The change in the conformation of TM3 might put the Asn
in TM3 of mMrgA2 receptor in the wrong orientation to bind sufficiently tight with adenine,
explaining the lack of binding or activation by adenine in mMrgA2, even though it has the
same pair of Asn as rMrgA. This could be tested by mutating the Pro94 of rMrgA to Val as in
mMrgA2 to see if this causes a loss in activity or by mutating the Val94 of mMrgA2 to Pro to
see if this leads to activity for adenine.
On the other hand, mMrgA5 receptor contains Pro in TM3 at the same position as in rMrgA
and the Asn146 of rMrgA is also conserved. However, the Asn88 in TM3 of rMrgA is replaced
with Tyr in mMrgA5 receptor. Here we suggest that mutation of Tyr87 to Asn in mMrgA5
might lead to adenine binding.
Summary and Conclusion
We predicted the 3-D structure of rMrgA receptor using homology to our MembStruk predicted
mMrgA1 and MrgC11 structures and we predicted the binding sites for adenine and its
derivatives using HierDock. The putative binding site is within TM3, 4, 5 and 6 with Asn88
in TM3 and Asn146 in TM4 serving as key residues in binding adenine. This Asn146 is
homologous to Asp161 in mMrgC11 receptor that we previously identified as a key residue
which was then validated experimentally. The side chain of Asn146 plays the role of the
thymine in the same way as in the Watson-Crick hydrogen bond geometry of the A-T DNA
base pair. It forms a bidentate hydrogen bond with both the N1 and N6 atom of adenine. The
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availability of the hydrogen bonds with these two Asn residues correlates with the binding
affinity of the ligand.
These studies of the rMrgA receptor provide targets for mutagenesis experiments to further
identify or validate important features in the binding site. This predicted binding site could be
used to identify other small molecule ligands. Experimental tests of such ligands might help
identify the endogenous ligand.
Electronic supplementary material
The supplementary material contains Table S1, the QM calculation of Gibbs free energies for
various tautomeric forms of 1MA and 6BAP and Figure S1, the putative binding sites predicted
from the HierDock scanning procedure. It also contains Figure S2, the Clustal-W multiple
sequence alignment of rat MrgA with mouse MrgAs.
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Figure 1.
The sequence alignment provided as an input for the homology modeling of rMrgA. The
transmembrane regions were obtained from the mMrgC11 and mMrgA1 structures. The N-
terminus (11 residues) and C-terminus (38 residues) were omitted because for class A GPCRs
(rhodopsin-like) they generally do not play a role in the binding of small ligands [45].
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Figure 2.
The ligand compounds used in docking studies for the rMrgA receptor. They are placed in
order of experimental binding affinity from top-left to bottom-right (except for adenosine
phosphates). No binding was detected experimentally for the ligands of the third row. For 1-
methyladenine (1MA) and 6-benzylaminopurine (6BAP), the most stable tautomeric forms are
shown together.
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Figure 3.
The predicted 3-D structure of the rMrgA receptor. The top part shows the view from the
extracellular side, while the bottom part shows the side view (with the extracellular part on
top).
A) Adenine (in spheres) is docked in the rMrgA receptor. The residues within 5 Å of adenine
are shown as sticks.
B) The rMrgA receptor (red) is overlapped with mMrgA1 (blue) and mMrgC11 (green).
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Figure 4.
Interhelical hydrogen bonds (dashed lines) in rMrgA receptor, as identified using HBPLUS
[46] (maximum D-A distance = 3.9 Å, minimum D-H-A angle = 90.0 °).
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Figure 5.
The predicted binding pockets of adenine (top) and guanine (bottom) in the rMrgA receptor.
All residues within 5 Å from the bound ligand are shown. The residue labels are colored
according to the binding energy contributions from non bond interaction with the ligand:
red: more favorable than -10 kcal/mol contribution (best),
green: between -10 and -4 kcal/mol,
blue: less favorable than -4 kcal/mol (worst).
The hydrogen bonds are indicated by dotted lines with the distance between the donor and
acceptor atoms. The number in parenthesis indicates the TM segment containing the residue.
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Figure 6.
The 5 Å binding pockets for various ligands in the rMrgA receptor. The same color scheme is
used as for Fig. 5. A) 1-Methyladenine, B) 6-benzylaminopurine, C) Hypoxanthine, D)
Adenosine.
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Figure 7.
The 5 Å binding pockets of adenosine phosphates in the rMrgA receptor. A) AMP, B) AMP,
C) ADP, D) ATP.
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Figure 8.
Comparison of calculated binding energies (left legend) with the experimental inhibition
constants (right legend) for rMrgA ligands as described in the Methods section, the calculated
energies are for the minimized structure (0K) without entropic contributions.
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Figure 9.
The sequence alignment of rat MrgA receptor with other receptors known to bind adenine
components of ligands: human A1 and A2A adenosine receptors and human P2Y1 purinergic
receptor. The residues predicted to play an important role in ligand binding are in bold face
and underlined.
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Table 1
Decomposition of total intermolecular interaction energies (kcal/mol) between ligand and rMrgA receptor,
calculated for the residues within 5 Å of the ligand.
Ligand Coulomb VDW Hbonds TOTAL
Adenine −2.37 (100) −11.63 (100) −28.17 (100) −42.17 (100)
1MA −1.20 (50) −16.16 (138) −23.87 (84) −41.23 (97)
6BAP −0.35 (14) −29.90 (257) −12.58 (44) −42.82 (101)
HPX −3.06 (129) −12.64 (108) −13.95 (49) −29.65 (70)
Guanine −3.27 (137) −14.26 (122) −16.59 (58) −34.12 (80)
Adenosine −1.23 (51) −22.84 (196) −12.95 (45) −37.02 (87)
The numbers in parentheses are percentages of interaction energies relative to that for adenine.
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Table 2
Computational alanine-scanning results for adenine/rMrgA (energies in kcal/mol).
I.E.(WT)a ΔI.E.(Ala)a
Asn88 −17.787 17.161 41%
Asn146 −12.819 12.275 29%
Met92 −4.741 2.844 7%
Phe83 −1.545 1.433 3%
His225 −1.505 1.349 3%
Leu174 −0.665 0.432 1%
Tyr95 −0.422 0.344 0.8%
Ile96 −0.450 0.333 0.8%
Phe178 −0.298 0.265 0.6%
Cys150 −0.494 0.207 0.5%
Thr170 −0.273 0.168 0.4%
Met91 −0.321 0.161 0.4%
Arg147 −0.360 0.091 0.2%
Pro85 −0.393 0.086 0.2%
Leu177 −0.102 0.066 0.2%
a
The intermolecular interaction energy (IE) for the wild type (WT, no mutation) is shown for all residues within 5 Å of the ligand. After mutating the
residue to Ala and minimizing, we recalculated the IE of the ligand to this Ala, IE(Ala).
b
The percentage change in binding of the mutant relative to the calculated total binding of WT is shown in the last column.
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